TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
16.59
0.00 (0.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close16.59
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.59 - 16.59
52 Week Range15.50 - 28.93
Volume0
Avg. Volume5,427,008
Market Cap28.177B
Beta (3Y Monthly)N/A
PE Ratio (TTM)20.44
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • This pharmaceutical company is like four biotechs in one,...
    CNBC Videoslast month

    This pharmaceutical company is like four biotechs in one,...

    Takeda Pharmaceutical Company President and CEO Christophe Weber sits down with CNBC's "Squawk on the Street" team after ringing the opening bell.

  • Japan Olympics boss suspected of campaign bribery
    Reuters Videoslast month

    Japan Olympics boss suspected of campaign bribery

    The president of Japan's Olympic Committee, Tsunekazu Takeda, has been indicted in France on allegations of corruption, an official has confirmed, related to his country's successful bid to host the 2020 Olympics. Lauren Anthony reports.

  • Moody'syesterday

    Shire Acq Inv Ireland Designated Activity Co -- Moody's announces completion of a periodic review of ratings of Shire Acq Inv Ireland Designated Activity Co

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Shire Acq Inv Ireland Designated Activity Co and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Moody's10 days ago

    Shire Acq Inv Ireland Designated Activity Co -- Moody's upgrades Shire's debt ratings to Baa2; stable outlook

    Moody's Investors Service ("Moody's") upgraded the senior unsecured debt ratings of Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC") and Baxalta Incorporated ("Baxalta"), subsidiaries of Shire plc (collectively "Shire") to Baa2 from Baa3. At the same time, Moody's withdrew the issuer rating on Shire plc. Please refer to the Moody's Investors Service's Policy for Withdrawal of Credit Ratings, available on its website, www.moodys.com.

  • Reuters17 days ago

    Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

    A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year. Takeda Pharmaceutical Co Ltd plans to seek approval for the experimental vaccine first in countries where the virus is endemic, rather than starting with the United States or Europe, whose rigorous reviews are often used as a benchmark worldwide, company executives told Reuters. The strategy mirrors one used by Sanofi SA, which licensed the world's first dengue vaccine, Dengvaxia, in endemic markets in 2015 before attempting to get approval from Western regulators, and forecast up to $1 billion in annual sales.

  • The Wall Street Journal18 days ago

    [$$] Takeda's Dengue Vaccine Works Safely, Company Says

    Co. said Tuesday a key trial showed its dengue vaccine protected children against the widespread tropical disease, raising hopes that a new weapon against the mosquito-borne infection without safety concerns could be approaching. An estimated 390 million people are infected with the mosquito-borne dengue virus in tropical regions around the world each year. SA, has been available so far to offer protection, and it has safety problems.

  • Reuters18 days ago

    Takeda dengue vaccine meets main goal of trial; detailed results to come

    Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the Japanese drugmaker's late-stage clinical trial. Takeda did not disclose how the vaccine performed in people who had never been previously exposed to dengue, a group that experienced an increased risk of severe disease with Sanofi's Dengvaxia, the world's first dengue vaccine. Sanofi had not collected blood samples on all subjects prior to beginning its trials.

  • Takeda to Plan Biggest Japan Company Bond Offering Ever
    Bloomberg20 days ago

    Takeda to Plan Biggest Japan Company Bond Offering Ever

    A spokeswoman for Takeda declined to comment. Takeda’s takeover of Shire -- the largest announced global deal of 2018 -- vaulted it into the ranks of the 10 biggest drugmakers by sales, but also more than doubled the Japanese firm’s borrowing level. Takeda’s management has stressed the importance of maintaining its credit ratings at investment grade, and hybrid debt can help achieve that as ratings firms may view the bonds as having an equity component depending on their structure.

  • TheStreet.comlast month

    Takeda Pharmaceutical CEO Talks Big Pharma Trends

    Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.

  • Reuterslast month

    France investigates Japan's Olympics chief on suspicion of corruption

    The president of Japan's Olympic Committee, Tsunekazu Takeda, is under formal investigation in France for suspected corruption related to Japan's successful bid for the 2020 Olympic Games, a French judicial source said on Friday. French financial prosecutors investigating a multi-million dollar payment made by Japan's bidding committee to a Singaporean consultancy questioned Takeda in Paris and he was placed under formal investigation on Dec. 10, the source told Reuters.

  • Reuterslast month

    Olympics-IOC opens ethics file on Takeda, to meet Friday

    The International Olympic Committee's ethics commission on Friday opened a file on Japan Olympic Committee chief Tsunekazu Takeda after a judicial source in France said he had been indicted by French prosecutors over the successful bid for the 2020 Olympic Games. The IOC Ethics commission has opened a file and will continue to monitor the situation - and is meeting today.

  • Benzingalast month

    The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...

  • Reuterslast month

    Takeda unlikely to sell OTC drug business - CEO

    Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire, Chief Executive Christophe Weber said on Monday. After the Shire deal, which closes on Tuesday, Takeda will have a stronger pipeline and be counted among the top 10 drugmakers by sales globally. "It's not our first priority," Weber told a news conference when asked whether Takeda would sell its OTC business.

  • Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth
    Market Realist2 months ago

    Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

    An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Xtandi revenue In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.

  • How Pfizer’s Sutent and Xalkori Have Performed
    Market Realist2 months ago

    How Pfizer’s Sutent and Xalkori Have Performed

    An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Sutent revenue In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.

  • Japan Inc heads abroad in $180bn deal rush
    MarketWatch2 months ago

    Japan Inc heads abroad in $180bn deal rush

    Japanese companies have embarked on the biggest overseas acquisition spree in more than 20 years, echoing the deal boom of the 1980s as they race to buy growth to offset a shrinking domestic market and ageing workforce. Corporate Japan splashed out nearly $180bn on 621 outbound deals so far this year, compared with 685 deals with a total value of almost $80bn for the whole of 2017, according to financial data provider Dealogic. Hitachi (HTHIY)  added another $6.4bn to Japan’s tally of deals on Monday after it bought an 80.1% stake in the power grids division of its Swiss-Swedish rival ABB (ABB) .

  • Moody's2 months ago

    Takeda Pharmaceutical Company Limited -- Moody's downgrades Takeda to Baa2; outlook stable

    Moody's Japan K.K. has downgraded to Baa2 from A2 the issuer and senior unsecured ratings of Takeda Pharmaceutical Company Limited. At the same time, Moody's has changed the ratings outlook to stable. "This transformative acquisition will cause Takeda's debt to increase almost six-fold, making the company one of the most leveraged pharmaceutical companies rated investment grade," says Moody's analyst Yukiko Asanuma.

  • What Are Tesaro’s Revenue Projections for Fiscal 2018?
    Market Realist2 months ago

    What Are Tesaro’s Revenue Projections for Fiscal 2018?

    How Is Tesaro Positioned in December? In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million. According to the company’s third-quarter earnings conference call, Tesaro is expected to have cash and cash equivalents worth $400 million on its balance sheet at the end of fiscal 2018.